06Jun 2023
Drug developer Servier's brain cancer drug slows tumor progession considerably

Drug developer Servier's brain cancer drug slows tumor progession considerably

Private drug developer Sevier Group announced positive results for its experimental brain cancer treatment, vorasidenib. The treatment has shown significant progress in slowing the progression of grade 2 glioma, a type of malignant brain tumor. In a study involving 331 patients who had not received prior treatment apart from surgery, vorasidenib delayed tumor growth for a median of 27.7 months compared to 11.1 months with a placebo. The drug also improved progression-free survival and delayed the need for further anticancer interventions like chemotherapy and radiation. Vorasidenib has received fast track designation from the US Food & Drug Administration (FDA) and the company is planning to submit a New Drug Application (NDA) to the FDA. Sevier Group acquired vorasidenib as part of its acquisition of Agios Pharmaceuticals Inc's cancer business in 2020.

  • #family health

Like

Save

Share